AbCellera Biologics Set to Announce FY Earnings Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy ABCL?
Source: seekingalpha
- Earnings Announcement Schedule: AbCellera Biologics (ABCL) is set to announce its FY earnings on February 24th after market close, with a consensus EPS estimate of -$0.63 and a revenue estimate of $36.29 million, reflecting a 26% year-over-year growth.
- Market Expectation Analysis: The projected revenue growth of 26% year-over-year indicates the company's ongoing potential in the biopharmaceutical sector, although the negative EPS suggests that the company is still in an investment phase and has not yet achieved profitability.
- Industry Conference Participation: AbCellera presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the biotechnology industry and attracting interest from potential investors.
- Patent Litigation Settlement: AbCellera settled patent litigation with Bruker regarding microfluidic device technology, a move that helps the company mitigate legal risks and focus on its core business development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABCL
Wall Street analysts forecast ABCL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.820
Low
9.00
Averages
9.00
High
9.00
Current: 3.820
Low
9.00
Averages
9.00
High
9.00
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
AbCellera Biologics Reports Earnings Beat, Shares Surge
- Earnings Beat: AbCellera Biologics reported a fourth-quarter 2025 loss of $0.03 per share, significantly better than the expected loss of $0.18, representing an 83.33% earnings outperformance that bolstered investor confidence.
- Significant Revenue Growth: The company saw a revenue increase of $39.80 million year-over-year, indicating its sustained growth potential in the biotechnology sector despite challenges faced in the third quarter of 2025.
- Strong Stock Performance: Following the earnings report, AbCellera's shares surged 9.32% in after-hours trading to $3.52, reflecting positive market sentiment and pushing its market capitalization to $963.86 million.
- Market Trend Analysis: Although the stock has gained 14.18% over the past 12 months, Benzinga's stock rankings indicate a negative price trend across all time frames, suggesting a cautious outlook on the company's future performance.
See More
AbCellera Biologics Set to Announce FY Earnings Results
- Earnings Announcement Schedule: AbCellera Biologics (ABCL) is set to announce its FY earnings on February 24th after market close, with a consensus EPS estimate of -$0.63 and a revenue estimate of $36.29 million, reflecting a 26% year-over-year growth.
- Market Expectation Analysis: The projected revenue growth of 26% year-over-year indicates the company's ongoing potential in the biopharmaceutical sector, although the negative EPS suggests that the company is still in an investment phase and has not yet achieved profitability.
- Industry Conference Participation: AbCellera presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the biotechnology industry and attracting interest from potential investors.
- Patent Litigation Settlement: AbCellera settled patent litigation with Bruker regarding microfluidic device technology, a move that helps the company mitigate legal risks and focus on its core business development.
See More
11 Stocks That Have Plummeted and Appear to Be Good Investment Opportunities
- Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
- Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued amidst the market downturn.
See More
Salesforce Shares and 10 Other Stocks That Have Plummeted and Appear to Be Good Investments
Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued following market crashes.
See More
AbCellera Biologics Initiates Phase 2 of pPREMIUM Clinical Trial
- Clinical Trial Advancement: AbCellera Biologics has dosed the first patients in the Phase 2 portion of its pPREMIUM clinical trial, marking a significant milestone in the development of antibody therapeutics, which is expected to drive further research and market applications.
- Successful Patient Recruitment: The initiation of this trial indicates positive progress in patient recruitment, laying a solid foundation for subsequent clinical data collection and analysis, thereby enhancing investor confidence.
- Strengthened R&D Strategy: By advancing the pPREMIUM project, AbCellera demonstrates its research capabilities in the biopharmaceutical sector, aiming to enhance its market competitiveness and meet the growing therapeutic demands.
- Optimistic Market Outlook: As the clinical trial progresses, AbCellera is poised to secure more collaboration opportunities and funding support in the future, further propelling the commercialization of its products.
See More
Axon Reports Q4 Revenue and Earnings Beat Estimates
- Significant Revenue Growth: Axon reported fourth-quarter revenue of $796.72 million, surpassing analyst expectations of $755.40 million, indicating strong market performance and sustained growth potential for the company.
- Improved Profitability: The company posted adjusted earnings of $2.15 per share, significantly exceeding the analyst estimate of $1.60 per share, reflecting Axon's success in cost control and operational efficiency.
- Stock Price Surge: Axon's shares jumped 16.2% in pre-market trading to $514.21, demonstrating a positive market reaction to its earnings report and indicating increased investor confidence in the company's future prospects.
- Market Impact Analysis: This earnings beat not only enhances Axon's market valuation but may also attract more investor attention, further solidifying the company's leadership position in the security technology sector.
See More
AbCellera Biologics Reports Earnings Beat, Shares Surge
- Earnings Beat: AbCellera Biologics reported a fourth-quarter 2025 loss of $0.03 per share, significantly better than the expected loss of $0.18, representing an 83.33% earnings outperformance that bolstered investor confidence.
- Significant Revenue Growth: The company saw a revenue increase of $39.80 million year-over-year, indicating its sustained growth potential in the biotechnology sector despite challenges faced in the third quarter of 2025.
- Strong Stock Performance: Following the earnings report, AbCellera's shares surged 9.32% in after-hours trading to $3.52, reflecting positive market sentiment and pushing its market capitalization to $963.86 million.
- Market Trend Analysis: Although the stock has gained 14.18% over the past 12 months, Benzinga's stock rankings indicate a negative price trend across all time frames, suggesting a cautious outlook on the company's future performance.
See More
AbCellera Biologics Set to Announce FY Earnings Results
- Earnings Announcement Schedule: AbCellera Biologics (ABCL) is set to announce its FY earnings on February 24th after market close, with a consensus EPS estimate of -$0.63 and a revenue estimate of $36.29 million, reflecting a 26% year-over-year growth.
- Market Expectation Analysis: The projected revenue growth of 26% year-over-year indicates the company's ongoing potential in the biopharmaceutical sector, although the negative EPS suggests that the company is still in an investment phase and has not yet achieved profitability.
- Industry Conference Participation: AbCellera presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the biotechnology industry and attracting interest from potential investors.
- Patent Litigation Settlement: AbCellera settled patent litigation with Bruker regarding microfluidic device technology, a move that helps the company mitigate legal risks and focus on its core business development.
See More
11 Stocks That Have Plummeted and Appear to Be Good Investment Opportunities
- Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
- Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued amidst the market downturn.
See More
Salesforce Shares and 10 Other Stocks That Have Plummeted and Appear to Be Good Investments
Market Opportunities: There are potential buying opportunities in the stock market due to recent significant declines in stock prices.
Investment Strategy: Investors may find value in stocks that have been overlooked or undervalued following market crashes.
See More
AbCellera Biologics Initiates Phase 2 of pPREMIUM Clinical Trial
- Clinical Trial Advancement: AbCellera Biologics has dosed the first patients in the Phase 2 portion of its pPREMIUM clinical trial, marking a significant milestone in the development of antibody therapeutics, which is expected to drive further research and market applications.
- Successful Patient Recruitment: The initiation of this trial indicates positive progress in patient recruitment, laying a solid foundation for subsequent clinical data collection and analysis, thereby enhancing investor confidence.
- Strengthened R&D Strategy: By advancing the pPREMIUM project, AbCellera demonstrates its research capabilities in the biopharmaceutical sector, aiming to enhance its market competitiveness and meet the growing therapeutic demands.
- Optimistic Market Outlook: As the clinical trial progresses, AbCellera is poised to secure more collaboration opportunities and funding support in the future, further propelling the commercialization of its products.
See More
